In the effort to fight against the pandemic of Covid-19, THZ ALLIANCE (the sister company of Wealth Inc.) is pleased to announce that we are the Authorised Exclusive Dealer of CanSino Biologics Ad5-nCoV vaccine in Malaysia.
AD5-nCOV, trade-named Convidecia, is a single-dose viral vector vaccine for COVID-19 developed by CanSino Biologics
The Recombinant Adenovirus Type-5 Vectored COVID-19 was developed by Beijing Institute of Biotechnology (Beijing, China) and CanSino Biologics (Tianjin, China).
The CanSino Biologics Ad5- nCoV vaccine candidate is a genetically engineered vaccine candidate with the replication-defective adenovirus type 5 as the vector to express spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain.
The production capacity for Ad5-NCov should reach 500 million doses in 2021, indicating its potential in halting the spread of virus through mass vaccination. The vaccine is approved for use by some countries in Asia, Europe, and Latin America.
Name of the vaccine product is Convidecia™. The route of administration would be in IM injection. The dosage regime is for single dose only (0.5mL per dose). The vaccine consists of target 5 ×10 viral particles in each dose. Besides, the vaccine does not contain preservatives or adjuvant.
The primary target population of this vaccine is the adults aged 18 and above. The vaccine can be stored and transported at temperatures of 2-8 °C, and production does not require biosafety level three laboratories, which is the case with inactivated vaccines, hence it is more accessible for developing countries with limited facilities. The shelf life of Convidecia™ is 24 months at 2-8 °C. The vaccine remains stable for 60 days at normal room temperature.
The CanSino Biologics Ad5-nCoV vaccine uses a weakened common cold virus — adenovirus, which infects human cells readily but is incapable of causing disease — to deliver genetic material that codes for the SARS-CoV-2 spike protein to the cells.
Subsequently, these cells then produce the spike protein and travel to the lymph nodes where the immune system creates antibodies that will recognise that spike protein and fight off the corona virus.
Unlike inactivated vaccines, CanSino’s vaccine is effective with a single dose and can bring dual protection, activating both humoral and cellular immunity simultaneously.
CanSino’s global multi-centre clinical trials in countries like Russia, Mexico, Pakistan, Argentina and Chile used uniform standards and organisational plans which involves 40,000 participants in total. Each centre had a principal investigator and a contract research organization as partners.
CanSino’s vaccine showed 90.98% efficacy rate in preventing severe disease and is effective to prevent 65.7% of symptomatic diseases. Nonetheless, the interim analysis in Pakistan alone showed 100% efficacy at preventing severe disease and 74.8% for symptomatic diseases.
Moreover, CanSino’s vaccine has the perfect safety profile as there were no severe adverse events reported in trials across the world. Ad5-nCoV’s Phase II and III trials involved aged participants and saw no serious adverse reactions, demonstrating that it is safe for the elderly.
Efficacy rate is “good” as a single dose vaccine.
Experts said the efficacy rate is “good” as a single dose vaccine. “Normally speaking, it is difficult for a dose to achieve high antibody levels without the second dose to enhance the immunology,” a Beijing-based immunological professor who asked not to be named told the Global Times.
A 70 percent effective single-dose vaccine may be more valuable than a two-dose regimen with 90 percent efficacy
Commented by the WHO Ad-hoc Expert Group previously in New England Journal of Medicine. Under the same efficacy rate and capacity conditions, the single-shot vaccine doubles the amount of people being immunized.
The single dose can vaccinate as many people as possible in the short term compared to traditional two-dose inactivated vaccines. Moreover, it relieves the pressure on production capacity and reduces the cost of administration and transportation.
Countries that are going to / started using the Vaccines
